NeuroOne to Host Investor Webinar Following Recent FDA Clearance for Neurological Technology

NeuroOne Medical Technologies Corporation announced it will conduct a virtual investor webinar on October 7, 2025, at 8:30 a.m. Eastern Standard Time to discuss business operations, recent FDA clearance, and corporate updates. The Minnesota-based medical technology company, trading on Nasdaq under the symbol NMTC, focuses on developing innovative solutions for patients suffering from neurological conditions.

The timing of this investor presentation follows significant regulatory progress for the company's medical technologies. NeuroOne has received FDA clearance for its minimally invasive and high-definition solutions designed for EEG recording, monitoring, ablation, drug delivery, and stimulation applications. These technologies target a range of neurological disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries.

The company's technological advancements could have substantial implications for both patient outcomes and healthcare economics. By developing less invasive procedures and more precise monitoring systems, NeuroOne aims to improve surgical care options while potentially reducing procedural costs for healthcare providers and patients. The webinar will provide investors and stakeholders with detailed insights into how these technologies function and their commercial potential in the neurological care market.

Beyond its current focus areas, NeuroOne has indicated potential expansion into additional therapeutic domains. The company may pursue applications for depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence integration. This broader vision suggests the company's platform technology could have wider applicability across multiple medical specialties, representing significant growth potential beyond its initial neurological focus.

The virtual roadshow format allows for broad participation from the investment community, with access available through both webcast and telephone dial-in options. Participants can join the webinar using the provided webcast link or by calling 888-506-0062 domestically or 973-528-0011 internationally with access code 619723. A recorded playback will be available through October 21, 2025, for those unable to attend the live session.

This investor communication comes at a critical juncture for medical technology companies operating in the neurological space. With an aging global population and increasing prevalence of neurological conditions, innovations that can improve treatment efficacy while controlling healthcare costs represent significant market opportunities. NeuroOne's upcoming presentation will provide important context about how the company plans to capitalize on these trends following its recent regulatory achievements.